The role of advanced glycation end products in vascular aging: which parameter is the most suitable as a biomarker?
Advanced glycation end products (AGEs) are involved in several pathophysiologic processes in vascular diseases, including progressive loss of elasticity of the vessel wall (arterial stiffness). Circulating soluble receptors for AGEs (sRAGE) act as a decoy and counterbalanced the harmful properties o...
Gespeichert in:
| Veröffentlicht in: | Journal of human hypertension 2021-03, Vol.35 (3), p.240-249 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 249 |
|---|---|
| container_issue | 3 |
| container_start_page | 240 |
| container_title | Journal of human hypertension |
| container_volume | 35 |
| creator | Mayer, Otto Gelžinský, Július Seidlerová, Jitka Mateřánková, Markéta Mareš, Štěpán Svobodová, Veronika Trefil, Ladislav Cífková, Renata Filipovský, Jan |
| description | Advanced glycation end products (AGEs) are involved in several pathophysiologic processes in vascular diseases, including progressive loss of elasticity of the vessel wall (arterial stiffness). Circulating soluble receptors for AGEs (sRAGE) act as a decoy and counterbalanced the harmful properties of AGEs as the natural protective factor. We compared the role of circulating or skin-deposed AGEs and sRAGE regarding the natural course of arterial stiffening. In a prospective cohort study, we longitudinally followed 536 general population-based subjects (subsample of Czech post-MONICA study). Aortic pulse-wave velocity (PWV) was measured twice (at baseline and after ~8 years of follow-up) using a SphygmoCor device (AtCor Medical Ltd), and the intraindividual change in PWV per year (∆PWV/year) was calculated. Concentrations of sRAGE and carboxymethyl lysine (circulating AGEs) were assessed at the follow-up visit by ELISA, while skin AGEs were measured using the autofluorescence-based device AGE Reader. Using multiple regressions, we found significant association between ∆PWV/year as a dependent variable, and both, sRAGE and skin AGEs as independent ones (each on its own model). However, the closest associations to ∆PWV/year were found for the ratio of these two factors (skin AGEs/sRAGE) [
β
coeff = 0.0747 (SE 0.0189),
p
|
| doi_str_mv | 10.1038/s41371-020-0327-3 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2503046610</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A655716241</galeid><sourcerecordid>A655716241</sourcerecordid><originalsourceid>FETCH-LOGICAL-c513t-af6f7b4b4fec2d7fbd02d29ec1103a42d9d2b521377d8c3b7674dea880873673</originalsourceid><addsrcrecordid>eNp1kk1v1DAQhi0EokvhB3BBlpAQlxR_JHGWS1VVfEmVuOzdmtiTjUtiL7ZT1H-Poy2FIpAPljzPvJ559RLykrMzzmT3LtVcKl4xwSomharkI7LhtWqrphHqMdmwbcOqrajZCXmW0jVja7F7Sk6kEEwyJTck7UakMUxIw0DB3oA3aOl-ujWQXfAUvaWHGOxicqLO0xtIZpkgUtg7v39Pf4zOjPQAEWbMGKlLNBfFOaRM0-Iy9EUaEgXauzBD_Ibx_Dl5MsCU8MXdfUp2Hz_sLj9XV18_fbm8uKpMw2WuYGgH1dd9PaARVg29ZcKKLRpeloda2K0VfSOKBcp2RvaqVbVF6DrWKdkqeUreHmXL_N8XTFnPLhmcJvAYlqSF7ESrGsV4QV__hV6HJfoynBZNcapu2_LnPbWHCbXzQ8gRzCqqL9qmUbwV9ap19g-qHIuzM8Hj4Mr7g4Y3fzSMCFMeU5iW1f_0EORH0MSQUsRBH6Irnt5qzvQaCH0MhC6B0GsgtCw9r-42W_oZ7X3HrwQUQByBVEp-j_H36v9X_Qnqw73N</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2503046610</pqid></control><display><type>article</type><title>The role of advanced glycation end products in vascular aging: which parameter is the most suitable as a biomarker?</title><source>Alma/SFX Local Collection</source><creator>Mayer, Otto ; Gelžinský, Július ; Seidlerová, Jitka ; Mateřánková, Markéta ; Mareš, Štěpán ; Svobodová, Veronika ; Trefil, Ladislav ; Cífková, Renata ; Filipovský, Jan</creator><creatorcontrib>Mayer, Otto ; Gelžinský, Július ; Seidlerová, Jitka ; Mateřánková, Markéta ; Mareš, Štěpán ; Svobodová, Veronika ; Trefil, Ladislav ; Cífková, Renata ; Filipovský, Jan</creatorcontrib><description>Advanced glycation end products (AGEs) are involved in several pathophysiologic processes in vascular diseases, including progressive loss of elasticity of the vessel wall (arterial stiffness). Circulating soluble receptors for AGEs (sRAGE) act as a decoy and counterbalanced the harmful properties of AGEs as the natural protective factor. We compared the role of circulating or skin-deposed AGEs and sRAGE regarding the natural course of arterial stiffening. In a prospective cohort study, we longitudinally followed 536 general population-based subjects (subsample of Czech post-MONICA study). Aortic pulse-wave velocity (PWV) was measured twice (at baseline and after ~8 years of follow-up) using a SphygmoCor device (AtCor Medical Ltd), and the intraindividual change in PWV per year (∆PWV/year) was calculated. Concentrations of sRAGE and carboxymethyl lysine (circulating AGEs) were assessed at the follow-up visit by ELISA, while skin AGEs were measured using the autofluorescence-based device AGE Reader. Using multiple regressions, we found significant association between ∆PWV/year as a dependent variable, and both, sRAGE and skin AGEs as independent ones (each on its own model). However, the closest associations to ∆PWV/year were found for the ratio of these two factors (skin AGEs/sRAGE) [
β
coeff = 0.0747 (SE 0.0189),
p
< 0.0001]. In a categorized manner, subjects with skin AGEs/sRAGE ratio ≥ 3.3 showed about twofold higher risk having ΔPWV/year ≥ 0.2 m/s [adjusted odds ratio was 2.09 (95% CI: 1.35–3.22),
p
= 0.001]. In contrast, neither circulating AGEs nor circulating AGEs/sRAGE showed any significant relation to ΔPWV/year. In conclusion, skin AGEs/sRAGE ratio seems to be a more sensitive biomarker of vascular aging than these single factors themselves or circulation status of AGEs.</description><identifier>ISSN: 0950-9240</identifier><identifier>EISSN: 1476-5527</identifier><identifier>DOI: 10.1038/s41371-020-0327-3</identifier><identifier>PMID: 32203073</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/499 ; 692/699/75 ; Advanced glycation end products ; Advanced glycosylation end products ; Aging ; Aorta ; Biological markers ; Biomarkers ; Blood circulation disorders ; Development and progression ; Diagnosis ; Epidemiology ; Glycosylation ; Health Administration ; Health aspects ; Lysine ; Medicine ; Medicine & Public Health ; Public Health ; Risk factors ; Skin ; Vascular diseases</subject><ispartof>Journal of human hypertension, 2021-03, Vol.35 (3), p.240-249</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Limited 2020</rights><rights>COPYRIGHT 2021 Nature Publishing Group</rights><rights>The Author(s), under exclusive licence to Springer Nature Limited 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c513t-af6f7b4b4fec2d7fbd02d29ec1103a42d9d2b521377d8c3b7674dea880873673</citedby><cites>FETCH-LOGICAL-c513t-af6f7b4b4fec2d7fbd02d29ec1103a42d9d2b521377d8c3b7674dea880873673</cites><orcidid>0000-0002-8023-3749</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27926,27927</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32203073$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mayer, Otto</creatorcontrib><creatorcontrib>Gelžinský, Július</creatorcontrib><creatorcontrib>Seidlerová, Jitka</creatorcontrib><creatorcontrib>Mateřánková, Markéta</creatorcontrib><creatorcontrib>Mareš, Štěpán</creatorcontrib><creatorcontrib>Svobodová, Veronika</creatorcontrib><creatorcontrib>Trefil, Ladislav</creatorcontrib><creatorcontrib>Cífková, Renata</creatorcontrib><creatorcontrib>Filipovský, Jan</creatorcontrib><title>The role of advanced glycation end products in vascular aging: which parameter is the most suitable as a biomarker?</title><title>Journal of human hypertension</title><addtitle>J Hum Hypertens</addtitle><addtitle>J Hum Hypertens</addtitle><description>Advanced glycation end products (AGEs) are involved in several pathophysiologic processes in vascular diseases, including progressive loss of elasticity of the vessel wall (arterial stiffness). Circulating soluble receptors for AGEs (sRAGE) act as a decoy and counterbalanced the harmful properties of AGEs as the natural protective factor. We compared the role of circulating or skin-deposed AGEs and sRAGE regarding the natural course of arterial stiffening. In a prospective cohort study, we longitudinally followed 536 general population-based subjects (subsample of Czech post-MONICA study). Aortic pulse-wave velocity (PWV) was measured twice (at baseline and after ~8 years of follow-up) using a SphygmoCor device (AtCor Medical Ltd), and the intraindividual change in PWV per year (∆PWV/year) was calculated. Concentrations of sRAGE and carboxymethyl lysine (circulating AGEs) were assessed at the follow-up visit by ELISA, while skin AGEs were measured using the autofluorescence-based device AGE Reader. Using multiple regressions, we found significant association between ∆PWV/year as a dependent variable, and both, sRAGE and skin AGEs as independent ones (each on its own model). However, the closest associations to ∆PWV/year were found for the ratio of these two factors (skin AGEs/sRAGE) [
β
coeff = 0.0747 (SE 0.0189),
p
< 0.0001]. In a categorized manner, subjects with skin AGEs/sRAGE ratio ≥ 3.3 showed about twofold higher risk having ΔPWV/year ≥ 0.2 m/s [adjusted odds ratio was 2.09 (95% CI: 1.35–3.22),
p
= 0.001]. In contrast, neither circulating AGEs nor circulating AGEs/sRAGE showed any significant relation to ΔPWV/year. In conclusion, skin AGEs/sRAGE ratio seems to be a more sensitive biomarker of vascular aging than these single factors themselves or circulation status of AGEs.</description><subject>692/499</subject><subject>692/699/75</subject><subject>Advanced glycation end products</subject><subject>Advanced glycosylation end products</subject><subject>Aging</subject><subject>Aorta</subject><subject>Biological markers</subject><subject>Biomarkers</subject><subject>Blood circulation disorders</subject><subject>Development and progression</subject><subject>Diagnosis</subject><subject>Epidemiology</subject><subject>Glycosylation</subject><subject>Health Administration</subject><subject>Health aspects</subject><subject>Lysine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Public Health</subject><subject>Risk factors</subject><subject>Skin</subject><subject>Vascular diseases</subject><issn>0950-9240</issn><issn>1476-5527</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kk1v1DAQhi0EokvhB3BBlpAQlxR_JHGWS1VVfEmVuOzdmtiTjUtiL7ZT1H-Poy2FIpAPljzPvJ559RLykrMzzmT3LtVcKl4xwSomharkI7LhtWqrphHqMdmwbcOqrajZCXmW0jVja7F7Sk6kEEwyJTck7UakMUxIw0DB3oA3aOl-ujWQXfAUvaWHGOxicqLO0xtIZpkgUtg7v39Pf4zOjPQAEWbMGKlLNBfFOaRM0-Iy9EUaEgXauzBD_Ibx_Dl5MsCU8MXdfUp2Hz_sLj9XV18_fbm8uKpMw2WuYGgH1dd9PaARVg29ZcKKLRpeloda2K0VfSOKBcp2RvaqVbVF6DrWKdkqeUreHmXL_N8XTFnPLhmcJvAYlqSF7ESrGsV4QV__hV6HJfoynBZNcapu2_LnPbWHCbXzQ8gRzCqqL9qmUbwV9ap19g-qHIuzM8Hj4Mr7g4Y3fzSMCFMeU5iW1f_0EORH0MSQUsRBH6Irnt5qzvQaCH0MhC6B0GsgtCw9r-42W_oZ7X3HrwQUQByBVEp-j_H36v9X_Qnqw73N</recordid><startdate>20210301</startdate><enddate>20210301</enddate><creator>Mayer, Otto</creator><creator>Gelžinský, Július</creator><creator>Seidlerová, Jitka</creator><creator>Mateřánková, Markéta</creator><creator>Mareš, Štěpán</creator><creator>Svobodová, Veronika</creator><creator>Trefil, Ladislav</creator><creator>Cífková, Renata</creator><creator>Filipovský, Jan</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8023-3749</orcidid></search><sort><creationdate>20210301</creationdate><title>The role of advanced glycation end products in vascular aging: which parameter is the most suitable as a biomarker?</title><author>Mayer, Otto ; Gelžinský, Július ; Seidlerová, Jitka ; Mateřánková, Markéta ; Mareš, Štěpán ; Svobodová, Veronika ; Trefil, Ladislav ; Cífková, Renata ; Filipovský, Jan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c513t-af6f7b4b4fec2d7fbd02d29ec1103a42d9d2b521377d8c3b7674dea880873673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>692/499</topic><topic>692/699/75</topic><topic>Advanced glycation end products</topic><topic>Advanced glycosylation end products</topic><topic>Aging</topic><topic>Aorta</topic><topic>Biological markers</topic><topic>Biomarkers</topic><topic>Blood circulation disorders</topic><topic>Development and progression</topic><topic>Diagnosis</topic><topic>Epidemiology</topic><topic>Glycosylation</topic><topic>Health Administration</topic><topic>Health aspects</topic><topic>Lysine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Public Health</topic><topic>Risk factors</topic><topic>Skin</topic><topic>Vascular diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mayer, Otto</creatorcontrib><creatorcontrib>Gelžinský, Július</creatorcontrib><creatorcontrib>Seidlerová, Jitka</creatorcontrib><creatorcontrib>Mateřánková, Markéta</creatorcontrib><creatorcontrib>Mareš, Štěpán</creatorcontrib><creatorcontrib>Svobodová, Veronika</creatorcontrib><creatorcontrib>Trefil, Ladislav</creatorcontrib><creatorcontrib>Cífková, Renata</creatorcontrib><creatorcontrib>Filipovský, Jan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection (ProQuest Medical & Health Databases)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of human hypertension</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mayer, Otto</au><au>Gelžinský, Július</au><au>Seidlerová, Jitka</au><au>Mateřánková, Markéta</au><au>Mareš, Štěpán</au><au>Svobodová, Veronika</au><au>Trefil, Ladislav</au><au>Cífková, Renata</au><au>Filipovský, Jan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The role of advanced glycation end products in vascular aging: which parameter is the most suitable as a biomarker?</atitle><jtitle>Journal of human hypertension</jtitle><stitle>J Hum Hypertens</stitle><addtitle>J Hum Hypertens</addtitle><date>2021-03-01</date><risdate>2021</risdate><volume>35</volume><issue>3</issue><spage>240</spage><epage>249</epage><pages>240-249</pages><issn>0950-9240</issn><eissn>1476-5527</eissn><abstract>Advanced glycation end products (AGEs) are involved in several pathophysiologic processes in vascular diseases, including progressive loss of elasticity of the vessel wall (arterial stiffness). Circulating soluble receptors for AGEs (sRAGE) act as a decoy and counterbalanced the harmful properties of AGEs as the natural protective factor. We compared the role of circulating or skin-deposed AGEs and sRAGE regarding the natural course of arterial stiffening. In a prospective cohort study, we longitudinally followed 536 general population-based subjects (subsample of Czech post-MONICA study). Aortic pulse-wave velocity (PWV) was measured twice (at baseline and after ~8 years of follow-up) using a SphygmoCor device (AtCor Medical Ltd), and the intraindividual change in PWV per year (∆PWV/year) was calculated. Concentrations of sRAGE and carboxymethyl lysine (circulating AGEs) were assessed at the follow-up visit by ELISA, while skin AGEs were measured using the autofluorescence-based device AGE Reader. Using multiple regressions, we found significant association between ∆PWV/year as a dependent variable, and both, sRAGE and skin AGEs as independent ones (each on its own model). However, the closest associations to ∆PWV/year were found for the ratio of these two factors (skin AGEs/sRAGE) [
β
coeff = 0.0747 (SE 0.0189),
p
< 0.0001]. In a categorized manner, subjects with skin AGEs/sRAGE ratio ≥ 3.3 showed about twofold higher risk having ΔPWV/year ≥ 0.2 m/s [adjusted odds ratio was 2.09 (95% CI: 1.35–3.22),
p
= 0.001]. In contrast, neither circulating AGEs nor circulating AGEs/sRAGE showed any significant relation to ΔPWV/year. In conclusion, skin AGEs/sRAGE ratio seems to be a more sensitive biomarker of vascular aging than these single factors themselves or circulation status of AGEs.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32203073</pmid><doi>10.1038/s41371-020-0327-3</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-8023-3749</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0950-9240 |
| ispartof | Journal of human hypertension, 2021-03, Vol.35 (3), p.240-249 |
| issn | 0950-9240 1476-5527 |
| language | eng |
| recordid | cdi_proquest_journals_2503046610 |
| source | Alma/SFX Local Collection |
| subjects | 692/499 692/699/75 Advanced glycation end products Advanced glycosylation end products Aging Aorta Biological markers Biomarkers Blood circulation disorders Development and progression Diagnosis Epidemiology Glycosylation Health Administration Health aspects Lysine Medicine Medicine & Public Health Public Health Risk factors Skin Vascular diseases |
| title | The role of advanced glycation end products in vascular aging: which parameter is the most suitable as a biomarker? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T18%3A50%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20role%20of%20advanced%20glycation%20end%20products%20in%20vascular%20aging:%20which%20parameter%20is%20the%20most%20suitable%20as%20a%20biomarker?&rft.jtitle=Journal%20of%20human%20hypertension&rft.au=Mayer,%20Otto&rft.date=2021-03-01&rft.volume=35&rft.issue=3&rft.spage=240&rft.epage=249&rft.pages=240-249&rft.issn=0950-9240&rft.eissn=1476-5527&rft_id=info:doi/10.1038/s41371-020-0327-3&rft_dat=%3Cgale_proqu%3EA655716241%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2503046610&rft_id=info:pmid/32203073&rft_galeid=A655716241&rfr_iscdi=true |